Add
BIOD to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| BIOD > SEC Filings for BIOD > Form 8-K on 11-Oct-2012 | All Recent SEC Filings |
11-Oct-2012
Other Events
On October 11, 2012, Biodel Inc. (the "Company") is hosting an Analyst / Investor Research and Development Meeting. The Company's presentation at the meeting includes the following updates to the Company's actual and projected timelines relating to its lead product development programs:
Recombinant human insulin-based ultra-rapid-acting insulin
·
Phase 2 clinical trial of BIOD-123 was initiated in the third calendar quarter of 2012.
·
Top line data projected in the third calendar quarter of 2013.
Analog-based ultra-rapid-acting insulin
·
Phase 1 clinical trial of BIOD-238 and BIOD-250 was initiated in the second half of calendar year 2012.
·
Top line data projected in the first calendar quarter of 2013.
Liquid formulation of glucagon for use as rescue treatment for severe hypoglycemia
·
Calendar year 2013 projections
o
File investigative new drug application.
o
Complete human factor study.
o
Conduct phase 1 "proof-of-concept" study.
·
Calendar year 2014 projections
o
Conduct pivotal study.
o
File new drug application (mid 2014).
|
|